Insmed Incorporated
INSM
Rank in Stocks
#1121
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Share Price
$93.98
Market Cap
$20.52B
Change (1 day)
-1.77%
Change (1 year)
-43.15%
Country
US
Trade Insmed Incorporated (INSM)
Category
Healthcare
Stock price history for Insmed Incorporated (INSM)
Highest end of day price: $100.34 on 2026-10-01
Lowest end of day price: $139.94 on 2000-06-01
Lowest end of day price: $139.94 on 2000-06-01
Stock price history of Insmed Incorporated from 2000 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -25.83% |
| 2025 | 163.90% |
| 2024 | 150.02% |
| 2023 | 48.62% |
| 2022 | -29.22% |
| 2021 | -27.29% |
| 2020 | 59.86% |
| 2019 | 62.30% |
| 2018 | -51.70% |
| 2017 | 128.88% |
| 2016 | -24.86% |
| 2015 | 16.87% |
| 2014 | -8.76% |
| 2013 | 145.55% |
| 2012 | 112.00% |
| 2011 | -49.13% |
| 2010 | -19.73% |
| 2009 | 46.16% |
| 2008 | -42.34% |
| 2007 | -13.04% |
| 2006 | -35.82% |
| 2005 | -15.49% |
| 2004 | -33.15% |
| 2003 | 447.28% |
| 2002 | -85.64% |
| 2001 | 16.21% |
| 2000 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
